Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00677820 · ClinicalTrials.gov registry record · Phase 4
A Prospective Study to Evaluate the Safety of a New Trivalent Intranasal Influenza Vaccine
A Phase 4 study, sponsored by MedImmune.
- Completed
- Registry status
- Phase 4
- Development phase
- 300
- Enrollment target
NCT00677820 is a Phase 4 study that has completed, run by MedImmune. The registered enrollment target is 300 participants.
The verdict
NCT00677820, a Phase 4 study, has completed, sponsored by MedImmune.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 300 participants
- Enrollment target
Study Summary
This prospective annual release study was designed to assess the safety of a trivalent influenza virus vaccine using a new strain recommended for the 2008-2009 influenza season not previously contained in the trivalent intranasal FluMist vaccine. Three hundred healthy adults received a single dose of vaccine or placebo and were followed for 180 days.
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL Trivalent influenza virus vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2008-06 |
| Est. Completion | 2008-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00677820
The ClinicalTrials.gov registry entry for NCT00677820 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MedImmune, which has 210 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00677820 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00677820 about?
NCT00677820 is a clinical study titled "A Prospective Study to Evaluate the Safety of a New Trivalent Intranasal Influenza Vaccine". This prospective annual release study was designed to assess the safety of a trivalent influenza virus vaccine using a new strain recommended for the 2008-2009 influenza season not previously contained in the trivalent intranasal FluMist vaccine. Three hundred healthy adults received a single dose o...
What is the current status of trial NCT00677820?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 300 participants. The study started on 2008-06. Estimated completion is 2008-12.
What interventions are being tested in trial NCT00677820?
The interventions under investigation include: Placebo (BIOLOGICAL), Trivalent influenza virus vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00677820?
This trial is sponsored by MedImmune, which has 210 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.